Rolf M.F. Berger

Prof. Dr. Rolf M.F. Berger

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet
Verified
Journal Article
Closed access
RBRolf M.F. Berger
Rolf M.F. Berger
MBMaurice Beghetti
Maurice Beghetti
THTilman Humpl
Tilman Humpl
GRGary E Raskob
Gary E Raskob
DID Dunbar Ivy
D Dunbar Ivy
RBRobyn J Barst
Robyn J Barst

29 July 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
DFDiederik E. Van Der Feen
Diederik E. Van Der Feen
GBGuido P. L. Bossers
Guido P. L. Bossers
QHQuint A. J. Hagdorn
Quint A. J. Hagdorn
JMJan-Renier Moonen
Jan-Renier Moonen
KKKondababu Kurakula
Kondababu Kurakula
Beatrijs BarteldsBeatrijs Bartelds
Beatrijs Bartelds
The transition from reversible to irreversible pulmonary arterial hypertension involves vascular senescence and can be countered by senolysis.

1 May 2014 in JACC
Verified
Journal Article
Closed access
WZWillemijn M.H. Zijlstra
Willemijn M.H. Zijlstra
JDJohannes Menno Douwes
Johannes Menno Douwes
BRBerman Rosenzweig
Berman Rosenzweig
SSSandor Schokker
Sandor Schokker
UKUsha Krishnan
Usha Krishnan
RBRolf M.F. Berger
Rolf M.F. Berger

1 March 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
FRFloris-Jan S. Ridderbos
Floris-Jan S. Ridderbos
DWDjoeke Wolff
Djoeke Wolff
ATAlbertus Timmer
Albertus Timmer
JMJoost P. van Melle
Joost P. van Melle
TETjark Ebels
Tjark Ebels
RBRolf M.F. Berger
Rolf M.F. Berger

29 August 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DIDunbar Ivy
Dunbar Ivy
ERErika B. Rosenzweig
Erika B. Rosenzweig
SASteven Abman
Steven Abman
MBMaurice Beghetti
Maurice Beghetti
Damien BonnetDamien Bonnet
Damien Bonnet
RBRolf M.F. Berger
Rolf M.F. Berger
Paediatric pulmonary arterial hypertension (PAH) shares common features with adult disease, but is associated with several additional disorders and challenges that require unique approaches. This article discusses recent advances, ongoing challenges and distinct approaches for caring for infants and children with PAH, as presented by the paediatric task force of the 7th World Symposium on Pulmonary Hypertension. We provide updates on diagnosing, classifying, risk-stratifying and treating paediatric pulmonary hypertension (PH) and identify critical knowledge gaps. An updated risk stratification tool and treatment algorithm is provided, now also including strategies for patients with associated cardiopulmonary conditions. Treatment of paediatric PH continues to be hindered by the lack of randomised controlled clinical trials. The challenging management of children failing targeted PAH therapy is discussed, including balloon atrial septostomy, lung transplantation and pulmonary-to-systemic shunt (Potts). A novel strategy using a multimodal approach for the management of PAH associated with congenital heart diseases with borderline pulmonary vascular resistance is included. Advances in diagnosing neonatal PH, especially signs and interpretation of PH by echocardiography, are highlighted. A team approach to the rapidly changing physiology of neonatal PH is emphasised. Challenges in drug approval are discussed, particularly the challenges of designing accurate paediatric clinical trials with age-appropriate end-points and adequate enrolment.

1 March 2016 in JACC
Verified
Journal Article
Closed access
JDJohannes M. Douwes
Johannes M. Douwes
THTilman Humpl
Tilman Humpl
DBDamien Bonnet
Damien Bonnet
MBMaurice Beghetti
Maurice Beghetti
DID. Dunbar Ivy
D. Dunbar Ivy
JBJ.T. Berger
J.T. Berger